Molecular aspects of the development of genetic syndromes associated with pancreatic neuroendocrine tumors

  • 作者: Mayev I1, Andreyev D1, Kucheryavyi Y.1, Dicheva D1, Andreyeva T2
  • 隶属关系:
    1. ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ
    2. ГБУЗ медико-санитарная часть №51 (Московский городской центр профпатологии) Департамента здравоохранения г. Москвы
  • 期: 卷 15, 编号 2 (2013)
  • 页面: 36-39
  • 栏目: Articles
  • URL: https://journals.rcsi.science/1815-1434/article/view/26898
  • ID: 26898

如何引用文章

全文:

详细

The paper provides a literature review of an update on the molecular genetic basis of inherited syndromes associated with the development of pancreatic neuroendocrine tumors, such as type 1 multiple neuroendocrine neoplasia, von Hippel–Lindau disease, type 1 neurofibromatosis, and tuberous sclerosis.

作者简介

I Mayev

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ

чл.-кор. РАМН, д-р мед. наук, проф., дир. Департамента медицинского образования и кадровой политики в здравоохранении Минздрава РФ, зав. каф. пропедевтики внутренних болезней и гастроэнтерологии МГМСУ

D Andreyev

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ

Email: dna-mit8@mail.ru
ассистент каф. пропедевтики внутренних болезней и гастроэнтерологии МГМСУ

Yu Kucheryavyi

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии МГМСУ

D Dicheva

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава РФ

канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии МГМСУ

T Andreyeva

ГБУЗ медико-санитарная часть №51 (Московский городской центр профпатологии) Департамента здравоохранения г. Москвы

врач-эндокринолог МСЧ №51 ДЗ г. Москвы

参考

  1. Маев И.В., Кучерявый Ю.А. Болезни поджелудочной железы. В 2 т. М.: Медицина, Шико, 2008.
  2. Muniraj T, Vignesh S, Shetty S et al. Pancreatic neuroendocrine tumors. Dis Mon 2013; 59 (1): 5–19.
  3. Jensen R.T, Berna M.J, Bingham D.B, Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113: 1807–43.
  4. Alexakis N, Connor S, Ghaneh P et al. Hereditary pancreatic endocrine tumours. Pancreatology 2004; 4 (5): 417–33.
  5. Jensen R.T, Norton J.A. Endocrine tumors of the pancreas and gastrointestinal tract. In: Feldman M, Friedman L.S, Brandt L.J, ed. Sleisinger and Fordtrans's gastrointestinal and liver disease, 9th ed. Philadelphia: WB Saunders; 2010: chap 32: 625.
  6. Эндокринология. Национальное руководство. Краткое издание. Под ред. И.И.Дедова, Г.А.Мельниченко. М.: ГЭОТАР - Медиа, 2011.
  7. Thakker R.V. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am 2000; 29: 541–67.
  8. Marx S, Spiegel A.M, Skarulis M.C et al. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 1998; 129: 484–94.
  9. Gibril F, Schumann M, Pace A, Jensen R.T. Multiple endocrine neoplasia type 1 and Zollinger - Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004; 83 (1): 43–83.
  10. Larsson C, Skogseid B, Oberg K et al. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 332: 85–7.
  11. Lemos M.C, Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29 (1): 22–32.
  12. Knudson A.G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820–3.
  13. Zhuang Z, Vortmeyer A.O, Pack S et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57: 4682–6.
  14. Agarwal S.K, Lee Burns A, Sukhodolets K.E et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci 2004; 1014: 189–98.
  15. Marx S.J. Molecular genetics of multiple endocrine neoplasia types and 2. Nat Rev Cancer 2005; 5: 367–75.
  16. Poisson A, Zablewska B, Gaudray P. Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett 2003; 189: 1–10.
  17. Yang Y, Hua X. In search of tumor suppressing functions of menin. Mol Cell Endocrinol 2007; 265–6: 34–41.
  18. Milne T.A, Hughes C.M, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin - dependent kinase inhibitors. Proc Natl Acad Sci USA 2005; 102: 749–54.
  19. Karnik S.K, Hughes C.M, Gu X et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 2005; 102: 14 659–64.
  20. Sato N, Sato M, Nakayama M et al. Cell cycle regulation of chromatin binding and nuclear localization of human Cdc7 ASK kinase complex. Gene Cell 2003; 8: 451–63.
  21. Schnepp R.W, Hou Z, Wang H et al. Functional interaction between tumor suppressor menin and activator of S-phase kinase. Cancer Res 2004; 64 (18): 6791–6.
  22. Agarwal S.K, Guru S.C, Heppner C et al. Menin interacts with the AP1 transcription factor JunD and represses JunD activated transcription. Cell 1999; 96: 143–52.
  23. Kim H, Lee J.E, Cho E.J et al. Menin, a tumor suppressor, represses JunD mediated transcriptional activity by association with an mSin3A histone deacetylase complex. Cancer Res 2003; 63: 6135–9.
  24. Agarwal S.K, Novotny E.A, Crabtree J.S et al. Transcriptional factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 2003; 100: 10 770–5.
  25. Heppner C, Bilimoria K.Y, Agarwal S.K et al. The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 2001; 20 (36): 4917–25.
  26. Lin S.Y, Elledge S.J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 2003; 113 (7): 881–9.
  27. Hashimoto M, Kyo S, Hua X et al. Role of menin in the regulation of telomerase activity in normal and cancer cells. Int J Oncol 2008; 33 (2): 333–40.
  28. Jin S, Mao H, Schnepp R.W et al. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 2003; 63: 4204–10.
  29. Sukhodolets K.E, Hickman A.B, Agarwal S.K et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene. Mol Cell Biol 2003; 23: 493–509.
  30. Averous J, Proud C.G. When translation meets transformation: the mTOR story. Oncogene 2006; 25 (48): 6423–35.
  31. Shida T, Kishimoto T, Furuya M et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65 (5): 889–93.
  32. Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol 2012; 3 (3): 182–8.
  33. Kasajima A, Pavel M, Darb-Esfahani S et al. mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2011; 18 (1): 181–92.
  34. Di Florio A, Adesso L, Pedrotti S et al. Src kinase activity coordinates cell adhesion and spreading with activation of mammalian target of rapamycin in pancreatic endocrine tumour cells. Endocr Relat Cancer 2011; 18 (5): 541–54.
  35. Wang Y, Ozawa A, Zaman S et al. The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Res 2011; 71 (2): 371–82.
  36. Corcos O, Couvelard A, Giraud S et al. Endocrine pancreatic tumors in von Hippel - Lindau disease: clinical, histological, and genetic features. Pancreas 2008; 37 (1): 85–93.
  37. Mukhopadhyay B, Sahdev A, Monson J.P et al. Pancreatic lesions in von Hippel - Lindau disease. Clin Endocrinol (Oxf) 2002; 57 (5): 603–8.
  38. Schmitt A.M, Schmid S, Rudolph T et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer 2009; 16 (4): 1219–27.
  39. Chou A, Toon C, Pickett J, Gill A.J. Von hippel - lindau syndrome. Front Horm Res 2013; 41: 30–49.
  40. Shuin T, Yamasaki I, Tamura K et al. Von Hippel - Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol 2006; 36 (6): 337–43.
  41. Ferner R.E. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 2007; 6 (4): 340–51.
  42. Mc Clatchey A.I. Neurofibromatosis. Annu Rev Pathol 2007; 2: 191–216.
  43. Rosner M, Hanneder M, Siegel N et al. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659 (3): 284–92.
  44. Schwartz R.A, Fernández G, Kotulska K, Jóźwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007; 57 (2): 189–202.
  45. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372 (9639): 657–68.
  46. Rosner M, Hanneder M, Siegel N et al. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658 (3): 234–46.
  47. Jiao Y, Shi C, Edil B.H et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331 (6021): 1199–203.

版权所有 © Consilium Medicum, 2013

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
 


##common.cookie##